Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Idelalisib
État du projet:
Terminé
Domaine thérapeutique:
Chronic lymphocytic leukemia
Fabricant:
Gilead Sciences, Inc.
Brand Name:
Zydelig
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0057-000
Strength:
100mg and 150mg tablets
Tumour Type:
Leukemia
Indications:
Chronic Lymphocytic Leukemia
Funding Request:
In combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)
Review Status:
Complete
Date NOC Issued:
Sponsor:
Gilead Sciences, Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016